Safety of biologics for the treatment of asthma in children and adolescents: a systematic review.

ABSTRACT:

Context

Despite the clinical benefits, the administration of biologics in asthma is not without adverse effects. However, there is a lack of information on the safety profile, particularly in children.

Objective

To provide a systematic review of the range of reported adverse events (AEs) of biologic treatments approved for paediatric asthma (Xolair, Nucala, Dupixent, Fasenra and Tezspire).

Data sources

Databases (MEDLINE, CENTRAL, Scopus and Web of Science) and one registry (ClinicalTrials.gov).

Study selection

This review included randomised clinical trials, prospective clinical studies, real-world studies, exploratory studies, registry analyses, case series and case reports, which met predefined inclusion criteria.

Data extraction

Study characteristics

SUBMITTER: Wirthgen E 

PROVIDER: S-EPMC12175077 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature